Drug Approval | March 15, 2023
Glenmark Pharmaceuticals receives ANDA approval for Clindamycin Hydrochloride Capsules USP
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
According to IQVIA sales data for the 12-month period ending December 2022, the Onglyza Tablets, 2.5 mg and 5 mg market achieved annual sales of approximately US $122.3 million
According to IQVIA sales data for the 12-month period ending October 2022, the Cardene Capsules, 20 mg and 30 mg market achieved annual sales of approximately US $10.9 million
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
U.S. FDA has issued Form 483 with six observations after an inspection of the company’s formulation manufacturing facility based out of Baddi
Glenmark’s current portfolio consists of 173 products authorized for distribution in the U.S. marketplace and 46 ANDA’s pending approval with the U.S. FDA
The company has 47 ANDA's pending approval with the U.S.FDA
The company reports revenue growth of 26% and PAT growth of 21% YoY
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Subscribe To Our Newsletter & Stay Updated
